Social | RheumNow

Open label, multicenter study of 70 Psoriasis pts treated w/ apremilast shows no change in aortic vascular inflammation (FDG-PET) at wks 16 & 52, but did decr. several cardiometabolic biomarkers (IL1b, ferritin) & 5-6% loss of SC fat https://t.co/iJOgZ5kHLb

Links:

https://bit.ly/3r3qi7j

Dr. John Cush @RheumNow ( View Tweet )

3 years 9 months ago

Retrospective study of PFAPA < 18yrs, 336 pts, Boys=Girls, peak onset ~age 1 yrs (less w/ yrs); 90% 1st Sxs under 5 yrs & <3% after age 10 yrs, Common Sxs: pharyngitis w fever, Cx adenitis, aphthous stomatitis, atyp skin rash. Incidence 0.86/10K/Yr https://t.co/1Mrp9bMnuE

Links:

https://bit.ly/3C3sqTa

Dr. John Cush @RheumNow ( View Tweet )

3 years 9 months ago

Metanalysis of 25 studies examined effects of NSAID therapy on COVID-19 outcomes and confirms NSAIDs do not increase the likelihood of SARS-CoV-2 infection and do not worsen outcomes in patients with COVID-19. https://t.co/FAJ58stmv1

Links:

https://go.nature.com/3qZg6Na

Dr. John Cush @RheumNow ( View Tweet )

3 years 10 months ago

Is PMR the Next Indication for Tocilizumab? About half of patients with steroid-dependent PMR were able to get off steroids altogether when they were started on tocilizumab (Actemra) infusions, a randomized phase III trial showed. https://t.co/LUMG4NnZzs https://t.co/zdFacyYyud

Links:

https://bit.ly/3f8AVmT

Dr. John Cush @RheumNow ( View Tweet )

3 years 10 months ago

Clinical Profiles Seen with NXP-2 Antibodies A recent review of the myositis associated autoantibody NXP-2 profiles its clinical associations with dermatomyositis (DM), calcinosis, severe myositis and, in some reports, with cancer. https://t.co/DTNohe66n1 https://t.co/Bu1qbi5Q1q

Links:

https://bit.ly/3DJRSyk

Dr. John Cush @RheumNow ( View Tweet )

3 years 10 months ago

Yoga Fails to Benefit Knee Osteoarthritis The Annals of Internal Medicine has published a study showing online yoga education and an unsupervised yoga program may improve physical function did not improve knee pain after 12 weeks and 24 weeks. https://t.co/tmWu4t3vgX https://t.co/bJCYaCIcGE

Links:

https://bit.ly/3xFPmoX

Dr. John Cush @RheumNow ( View Tweet )

3 years 10 months ago

IL-6i in Behcets? Lit Review finds 25 articles papers, 74 pts (31 TNFi naive, 45 TNFi prior Rx). Pts Rx w/ tocilizumab IV. TCZ given for vascular, CNS , ocular & mucocutaneous. TCZ was effective in 87% TNF naive & 80% in TNFi Experienced pts. https://t.co/jdJ9H04lnE https://t.co/yoxrKiIVW2

Links:

https://bit.ly/3BXjvTd

Dr. John Cush @RheumNow ( View Tweet )

3 years 10 months ago

Are we set for the next "Twindemic"? - Continuation and evolution of COVID BA.5 to? - Flourishing Influenza in a population who has vaccine burnout? Some predicting severe flu based on Australia’s 2022 flu season, climate change, more https://t.co/qWuhWjaAFa

Links:

https://bit.ly/3S2HWUF

Dr. John Cush @RheumNow ( View Tweet )

3 years 10 months ago

NIH: 27 pts w/ ROSAH (retinal dystrophy, optic N. edema, splenomegaly, anhidrosis, headache) syndrome, due to dominant mutation ALPK1 - an autoinflammatory Dz w fevers, HA, Abnl CNS MRI, deforming arthritis, AA amyloidosis . https://t.co/Pyb3QNrPnB https://t.co/wxtwOGpKFr

Links:

https://bit.ly/3BwpIUK

Dr. John Cush @RheumNow ( View Tweet )

3 years 10 months ago

Is there link between PsA & autoinflammatory Dz? Study of 120 #PsA pts found 31% w/ AID gene variants (AP1S3, PLCG2, NOD2, NLRP12, all monoallelic variants adn 1/2 genes assoc w/ autosomal dominant disorders. https://t.co/KaL7jheDZ6 https://t.co/09CSW2W3tn

Links:

https://bit.ly/3xEDlA0

Dr. John Cush @RheumNow ( View Tweet )

3 years 10 months ago

Cohort Hip & Cohort Knee (CHECK) study of biomarkers (serum hs-CRP, sCOMP, sPINP sOC and urine uCTX-2) in1002 pts w/ hip or knee OA. Shows CRP, uCTX-2 & sPINP (OR 1.11-1.40) were assoc w/ nocturnal & walking pain, but not fatigue https://t.co/EOU6i24KLO https://t.co/VQWfeLR01x

Links:

https://bit.ly/3BVCCNu

Dr. John Cush @RheumNow ( View Tweet )

3 years 10 months ago

Hydroxychloroquine Dosing and SLE Flares JAMA cohort study examining HCQ dosing in patients with SLE suggests that HCQ doses of 5 mg/kg per day or less, was associated with a higher risk of lupus flares, including moderate or severe lupus flares. https://t.co/B5HqxWDqD3 https://t.co/4crIFBV9XP

Links:

https://bit.ly/3LHJRvP

Dr. John Cush @RheumNow ( View Tweet )

3 years 10 months ago

Topics

Tweets

Do you get our email newsletter?